Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leronlimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- CytoDyn
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (leronlimab), Intravenous (carboplatin, Bevacizumab), Oral (trifluridine And Tipiracil)
01
Overview
Leronlimab + chemotherapy refers to investigational combination regimens involving **leronlimab**, a humanized IgG4 monoclonal antibody targeting the chemokine receptor **CCR5**, used together with various chemotherapy agents. Leronlimab binds CCR5, inhibiting its role in tumor metastasis, immune cell trafficking, and the tumor microenvironment. In clinical trials, it is combined with standard chemotherapy drugs such as trifluridine and tipiracil (TAS-102), bevacizumab, or carboplatin, primarily for **CCR5-positive, microsatellite stable metastatic colorectal cancer (MSS mCRC)** and **CCR5-positive metastatic triple-negative breast cancer (mTNBC)**. The combinations are investigated for enhancing overall response rate, progression-free survival, and overall survival in patients who have progressed after standard chemotherapies[1][2][3][4][5].
- Other names
- leronlimab + trifluridine + tipiracil + bevacizumableronlimab + carboplatin
02
Targets
Beyond the preview
Go deeper on leronlimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leronlimab + chemotherapy.